The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Simultaneous silencing of TGF-β1 and COX-2 reduces human skin hypertrophic scar through activation of fibroblast apoptosis
Abstract
// Jia Zhou 1, * , Yixuan Zhao 1, * , Vera Simonenko 2, * , John J. Xu 3 , Kai Liu 1 , Deling Wang 3 , Jingli Shi 3 , Tianyi Zhong 3 , Lixia Zhang 3 , Lun Zeng 4 , Bin Huang 4 , Shenggao Tang 5 , Alan Y. Lu 5 , A. James Mixson 6 , Yangbai Sun 1 , Patrick Y. Lu 2 and Qingfeng Li 1 1 Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China 2 Sirnaomics, Inc., Gaithersburg, MD, USA 3 Suzhou Sirnaomics Pharmaceuticals, Ltd., Biobay, Suzhou, China 4 Guangzhou Xiangxue Pharmaceuticals, Co. Ltd., Guangzhou, China 5 Guangzhou Nanotides Pharmaceuticals, Co. Ltd., Guangzhou, China 6 Department of Pathology, School of Medicine, University of Maryland, Baltimore, MD, USA * These authors contributed equally to this work and share co-first authorship Correspondence to: Qingfeng Li, email: dr.liqingfeng@shsmu.edu.cn Patrick Y. Lu, email: plu@sirnaomics.com Yangbai Sun, email: drsunyb@foxmail.com Keywords: siRNA therapeutics, hypertrophic scar, TGF-β1, COX-2, synergistic effect Received: November 16, 2016 Accepted: August 26, 2017 Published: September 14, 2017 ABSTRACT Excessive skin scars due to elective operations or trauma represent a challenging clinical problem. Pathophysiology of hypertrophic scars entails a prolonged inflammatory and proliferative phase of wound healing. Over expression of TGF-β1 and COX-2 play key regulatory roles of the aberrant fibrogenic responses and proinflammatory mediators. When we silenced TGF-β1 and COX-2 expression simultaneously in primary human fibroblasts, a marked increase in the apoptotic cell population occurred in contrast to those only treated with either TGF-β1 or COX-2 siRNA alone. Furthermore, using human hypertrophic scar and skin graft implant models in mice, we observed significant size reductions of the implanted tissues following intra-scar administration of TGF-β1/COX-2 specific siRNA combination packaged with Histidine Lysine Polymer (HKP). Gene expression analyses of those treated tissues revealed silencing of the target gene along with down regulations of pro-fibrotic factors such as α-SMA, hydroxyproline acid, Collagen 1 and Collagen 3. Using TUNEL assay detection, we found that the human fibroblasts in the implanted tissues treated with the TGF-β1/COX-2 siRNAs combination exhibited significant apoptotic activity. Therefore we conclude that a synergistic effect of the TGF-β1/COX-2siRNAs combination contributed to the size reductions of the hypertrophic scar implants, through activation of fibroblast apoptosis and re-balancing between scar tissue deposition and degradation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“whereas enhanced expression of TGF-β1 mRNA was found in both keloids and hypertrophic scars [60].”
From Silver Nanoparticles-Composing Alginate/Gelatine Hydrogel Improves Wound Healing In Vivo (2020) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541 · cited 1×
“Understanding the pathophysiology of fibrosis may lead to a novel therapeutic with improved clinical benefit [2].”
BackgroundLevinson, H. (2013) · Advances in Wound Care · doi:10.1089/wound.2012.0389 · Cited by 30
Regulation of Transforming Growth Factor-β-dependent Cyclooxygenase-2 Expression in Fibroblasts
Matsumura, T., Suzuki, T., Aizawa, K., Sawaki, D., Munemasa, Y., Ishida, J., & Nagai, R. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.014639 · Cited by 28
Research works printed but not linked: 30
- Ziegler, 2002, International clinical recommendations on scar management, Plastic and reconstructive surgery, 110, 560, 10.1097/00006534-200208000-00031 · DOI · Paper page
- Nanchahal, 2005, Advances in the modulation of cutaneous wound healing and scarring, BioDrugs, 19, 363, 10.2165/00063030-200519060-00004 · DOI
- Tredget, 2013, The molecular mechanism of hypertrophic scar, Journal of cell communication and signaling, 7, 239, 10.1007/s12079-013-0195-5 · DOI
- Ghahary, 1997, Hypertrophic scars, keloids, and contractures. The cellular and molecular basis for therapy, Surg Clin North Am, 77, 701, 10.1016/S0039-6109(05)70576-4 · DOI · Paper page
- Maini, 2006, Fibroblast migration and collagen deposition during dermal wound healing: mathematical modelling and clinical implications, Philos Trans A Math Phys Eng Sci, 364, 1385, 10.1098/rsta.2006.1773 · DOI · Paper page
- Tredget, 2001, Myofibroblasts and apoptosis in human hypertrophic scars: the effect of interferon-alpha2b, Surgery, 130, 798, 10.1067/msy.2001.116453 · DOI
- Huang, 2002, Synthetic TGF-beta antagonist accelerates wound healing and reduces scarring, FASEB J, 16, 1269, 10.1096/fj.02-0103fje · DOI
- Zimmerman, 2009, A novel TGF-beta antagonist speeds reepithelialization and reduces scarring of partial thickness porcine burns, Journal of burn care & research, 30, 329, 10.1097/BCR.0b013e31819a6369 · DOI
- Choi, 2012, Autophagy promotes intracellular degradation of type I collagen induced by transforming growth factor (TGF)-beta1, The Journal of biological chemistry, 287, 11677, 10.1074/jbc.M111.308460 · DOI · Paper page
- Wang, 2010, Nonsteroidal anti-inflammatory drugs for wounds: pain relief or excessive scar formation?, Mediators of inflammation, 2010, 413238
- Oberyszyn, 2004, The impact of cyclooxygenase-2 mediated inflammation on scarless fetal wound healing, The American journal of pathology, 165, 753, 10.1016/S0002-9440(10)63338-X · DOI
- Shivkar, 2004, Involvement of prostaglandins in inflammation induced by latex of Calotropis procera, Mediators of inflammation, 13, 151, 10.1080/09511920410001713583 · doi:10.1080/09511920410001713583
- Mixson, 2008, Systemic delivery of HK Raf-1 siRNA polyplexes inhibits MDA-MB-435 xenografts, Cancer Gene Ther, 15, 485, 10.1038/cgt.2008.29 · DOI
- Li, 2008, Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth, Molecular Cancer Therapeutics, 7, 1355, 10.1158/1535-7163.MCT-08-0104 · DOI
- Dai, 2007, Establishment of a hypertrophic scar model by transplanting full-thickness human skin grafts onto the backs of nude mice, Plastic and reconstructive surgery, 119, 104, 10.1097/01.prs.0000244828.80490.62 · doi:10.1097/01.prs.0000244828.80490.62
- Van De Water, 2006, A TGF-beta1-dependent autocrine loop regulates the structure of focal adhesions in hypertrophic scar fibroblasts, The Journal of investigative dermatology, 126, 963, 10.1038/sj.jid.5700187 · DOI
- Tredget, 2011, Human hypertrophic scar-like nude mouse model: characterization of the molecular and cellular biology of the scar process, Wound repair and regeneration, 19, 274, 10.1111/j.1524-475X.2011.00672.x · DOI
- Ting, 2003, Ontogenetic transition in fetal wound transforming growth factor-beta regulation correlates with collagen organization, The American journal of pathology, 163, 2459, 10.1016/S0002-9440(10)63601-2 · DOI
- Dooley, 2005, Abrogation of transforming growth factor-beta signaling by SMAD7 inhibits collagen gel contraction of human dermal fibroblasts, The Journal of biological chemistry, 280, 21570, 10.1074/jbc.M502071200 · DOI
- Wahli, 2005, Genetic- or transforming growth factor-beta 1-induced changes in epidermal peroxisome proliferator-activated receptor beta/delta expression dictate wound repair kinetics, The Journal of biological chemistry, 280, 18163, 10.1074/jbc.M412829200 · DOI
- Linge, 2007, A role for TGF-beta1-induced cellular responses during wound healing of the non-scarring early human fetus?, The Journal of investigative dermatology, 127, 2656, 10.1038/sj.jid.5700951 · DOI
- Sheng, 2005, Ontogeny of expression of transforming growth factor-beta and its receptors and their possible relationship with scarless healing in human fetal skin, Wound Repair and Regeneration, 13, 68, 10.1111/j.1067-1927.2005.130109.x · DOI
- Hao, 2015, Liposome-Adenoviral hTERT-siRNA Knockdown in Fibroblasts from Keloids Reduce Telomere Length and Fibroblast Growth, Cell Biochem Biophys, 72, 405, 10.1007/s12013-014-0476-5 · DOI
- Dai, 2014, siRNA-targeting transforming growth factor-beta type I receptor reduces wound scarring and extracellular matrix deposition of scar tissue, J Invest Dermatol, 134, 2016, 10.1038/jid.2014.84 · DOI
- Shimada, 2014, siRNA knockdown of tissue inhibitor of metalloproteinase-1 in keloid fibroblasts leads to degradation of collagen type I, J Invest Dermatol, 134, 818, 10.1038/jid.2013.396 · DOI
- Sadeghpour, 2015, Surface decorations of poly(amidoamine) dendrimer by various pendant moieties for improved delivery of nucleic acid materials, Colloids Surf B Biointerfaces, 132, 85, 10.1016/j.colsurfb.2015.05.006 · DOI
- Demarchez, 1999, Wound healing of human skin transplanted onto the nude mouse after a superficial excisional injury: human dermal reconstruction is achieved in several steps by two different fibroblast subpopulations, Archives of dermatological research, 291, 591, 10.1007/s004030050460 · DOI
- Zhang, 2017, A novel elastic liposome for skin delivery of papain and its application on hypertrophic scar, Biomed Pharmacother, 87, 82, 10.1016/j.biopha.2016.12.076 · DOI
- Hu, 2014, Amentoflavone inhibits angiogenesis of endothelial cells and stimulates apoptosis in hypertrophic scar fibroblasts, Burns, 40, 922, 10.1016/j.burns.2013.10.012 · DOI
- Yang, 2014, Progress of targeting transforming growth factor-beta1 small interfering RNA in liver fibrosis, Chin Med Sci J, 29, 231, 10.1016/S1001-9294(14)60076-6 · doi:10.1016/s1001-9294(14)60076-6
Cited by
Therapeutic siRNA: state of the art
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586
Self-citationRNAi therapeutic and its innovative biotechnological evolution
Weng, Y., Xiao, H., Zhang, J., Liang, X.-J., & Huang, Y. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.04.012 · Cited by 286
Silver Nanoparticles-Composing Alginate/Gelatine Hydrogel Improves Wound Healing In Vivo
Diniz, F., Maia, R., de Andrade, L. R., Andrade, L., Vinicius Chaud, M., da Silva, C., Corrêa, C., de Albuquerque Junior, R., Pereira da Costa, L., Shin, S., et al. (2020) · Nanomaterials · doi:10.3390/nano10020390 · Cited by 259
Small interfering RNA: Discovery, pharmacology and clinical development—An introductory review
Ranasinghe, P., Addison, M. L., Dear, J. W., & Webb, D. J. (2023) · British Journal of Pharmacology · doi:10.1111/bph.15972 · Cited by 138
Insights on drug and gene delivery systems in liver fibrosis
Vyas, K., & Patel, M. M. (2023) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2023.100779 · Cited by 30
Metadata
- Authors
- Zhou, J., Zhao, Y., Simonenko, V., Xu, J. J., Liu, K., Wang, D., Shi, J., Zhong, T., Zhang, L., Zeng, L., Huang, B., Tang, S., Lu, A. Y., Mixson, A. J., Sun, Y., Lu, P. Y., & Li, Q.
- Affiliations
- Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- Sirnaomics, Inc., Gaithersburg, MD, USA
- Suzhou Sirnaomics Pharmaceuticals, Ltd., Biobay, Suzhou, China
- Guangzhou Xiangxue Pharmaceuticals, Co. Ltd., Guangzhou, China
- Guangzhou Nanotides Pharmaceuticals, Co. Ltd., Guangzhou, China
- Department of Pathology, School of Medicine, University of Maryland, Baltimore, MD, USA
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-09-14
- Volume
- 8
- Issue
- 46
- Pages
- 80651-80665
- ISSN
- 1949-2553
- Cited by
- 54
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.